Search clinical trials for: Pembrolizumab

Total 2278 results

Mayo Clinic
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States
Immodulon Therapeutics Ltd

Terminated

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (MODULATE)

Metastatic Cancer

France, United Kingdom
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Olaparib in LA-HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; United States Department of Defense

Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
European Society for Blood and Marrow Transplantation
EULAR

Withdrawn

Autologous Stem Cell Transplantation: International Lupus Trial (ASTIL)

REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS

France
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

Renal Cell Carcinoma

Korea, Republic of, Spain, United States, Netherlands, Ireland, Canada, United Kingdom, Poland, Italy, Australia, Russian Federation, Belgium, Israel, France, Greece, Czechia, Switzerland, Austria, Germany, Japan
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Triple Negative Breast Cancer

United States, Australia
National Cancer Institute (NCI)

Recruiting

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Eli Lilly and Company; Merck Sharp & Dohme LLC

Completed

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
University of Miami
Merck Sharp & Dohme LLC

Terminated

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Cervical Cancer

United States
Oncopeptides AB

Terminated

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function (BRIDGE)

Multiple Myeloma | Renal Impairment

Greece, Czechia, Poland
NCIC Clinical Trials Group

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Pathologic Stage... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Hodgkin Lymphoma

United States, Brazil, Colombia, Czechia, France, Germany, Greece, Guatemala, Italy, Korea, Republic of, Mexico, Netherlands, Slovakia, South Africa, Spain, United Kingdom
Inge Marie Svane
Technical University of Denmark

Recruiting

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Malignant Melanoma

Denmark
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03)

Gastric Cancer

China, Spain, Korea, Republic of, Canada, Italy, Poland, Japan, United Kingdom, Brazil, Taiwan, United States, Germany, Netherlands, Russian Federation
Kobe Minimally Invasive Cancer Center
Merck Sharp & Dohme LLC

Not yet recruiting

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC (Evolution)

Locally Advanced Non-small Cell Lung Cancer
Oncopeptides AB

Terminated

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients (PORT)

RRMM

Bulgaria, United States, Czechia, Hungary, Ukraine
ETOP IBCSG Partners Foundation
Merck Sharp & Dohme LLC; Frontier Science Foundation, Hellas

Completed

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso)

Pleural Mesothelioma Malignant Advanced

United Kingdom, Switzerland, Spain
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Malignant Melanoma
Jules Bordet Institute

Recruiting

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Melanoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Mesothelioma, Malignant | Bladder Cancer | Gastrointestinal Cancer | Merkel Cell Carcinoma | Non-melanoma Skin Cancer | MSI-H Colorectal Cancer

Belgium
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Not yet recruiting

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer (PRIAM)

Urologic Neoplasms | Urogenital Neoplasms | Penile Cancer | Male Urogenital Diseases | Penile Squamous Cell Carcinoma | Locally Advanced Penile Carcinoma
Nikolaj Frost MD
Roche Pharma AG; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...

Recruiting

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)

Non-Small Cell Lung Cancer Metastatic

Germany
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study (LEAP-001)

Endometrial Neoplasms

China
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) (LEAP-001)

Endometrial Neoplasms

Brazil, United States, Argentina, Australia, Austria, Belgium, Canada, China, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Shirish Gadgeel
Merck Sharp & Dohme LLC

Withdrawn

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC (HFHS 21-01)

Non Small Cell Lung Cancer | PD-L1 Gene Mutation | Advanced Lung Non-Small Cell Carcinoma
The Cleveland Clinic

Completed

Rituximab in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
Beijing Tongren Hospital

Recruiting

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy | Pembrolizumab

China
National Cancer Institute (NCI)

Suspended

A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Melanoma

United States
Julia K. Rotow, MD
Inivata

Active, not recruiting

Plasma-Adapted First-Line Pembro In NSCLC

Metastatic Non-Small Cell Lung Cancer | NSCLC Stage IV

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Myeloid Diseases

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Triple Negative Breast Cancer (TNBC)
University of Chicago

Active, not recruiting

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Breast Cancer | Triple Negative Breast Neoplasms

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC

Terminated

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

Metastatic Breast Cancer

United States
BioNTech US Inc.
Merck Sharp & Dohme LLC

Completed

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung

United States
University of California, San Francisco
Merck Sharp & Dohme LLC; Avon Foundation

Terminated

Reversing Therapy Resistance With Epigenetic-Immune Modification

Breast Neoplasms

United States
European Organisation for Research and Treatment...

Unknown

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

France, Belgium, Netherlands, Germany, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Grade 3a Follicular Lymphoma

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein Proficient

United States
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
NuCana plc

Recruiting

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Neoplasm Malignant | Pleural... and other conditions

United Kingdom
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
Tianhong Li
National Cancer Institute (NCI); LabyRx Immunologic Therapeutics

Recruiting

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Adenocarcinoma | Advanced Adenocarcinoma | Recurrent Adenocarcinoma

United States
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Recruiting

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Metastatic Pancreatic Cancer

United States

Search clinical trials for: Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations